Logo

Jazz First Patient Enrolled in P-III (IMforte) Trial of Zepzelca (lurbinectedin) + Tecentriq for Extensive-Stage Small Cell Lung Cancer

Share this

Jazz First Patient Enrolled in P-III (IMforte) Trial of Zepzelca (lurbinectedin) + Tecentriq for Extensive-Stage Small Cell Lung Cancer

Shots:

  • The first patient has enrolled in a P-III (IMforte) trial to evaluate the efficacy, safety, and PK of Zepzelca + Tecentriq (PD-L1 inhibitor) vs SoC in patients with es-SCLC, following induction therapy with carboplatin, etoposide, and atezolizumab. The trial is being conducted in collaboration with F. Hoffmann-La Roche
  • The primary objective is to determine the ability to improve outcomes for patients with ES-SCLC, compared with SoC as measured by PFS and OS
  • Additionally, the trial will support the sNDA for Zepzelca + Tecentriq as a 1L maintenance treatment of ES-SCLC. Zepzelca is an alkylating drug that binds guanine residues within DNA

Ref: PR Newswire | Image: Jazz 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions